Member Info for inanaco

I know boom but that is more of a Platform presentation rather than an individual pipeline member ... narrowing further by adding market size of Triple negative etc.

you will just confuse even more, so your now saying explain the science not just of the vaccine but the synergy with Pd1 and the marketing potential of each of scancells pipeline ... they have 20 mins not 3 hours ... what i clearly suggested was Videos on all aspects, something potential investors can follow at a pace that suits them Transmit in the language of the audience ? what does that mean, any potential investor will not have a clue about the language in the bio world apart from the dominate word across all markets "money" when your talking about actually investing in a "scientific research company" its pretty difficult not to go technical

Lets look at TCR .. bioNtech ........... its a harsh treatment in that your expanding a modified T cell outside the body and injecting back in to the patient a highly targeted bunch of t cells cells ... in other words an "instant" immune response at full power. well that would be a wake up call ........ better than any alarm clock .... Yet BioNtech are happy to proceed with moditope .... if any risk was associated with auto immunity BioNtech would not be involved the treatment is far more intense than any Modi1 injection so this relentless screening continues in real Blood ......... and so far after 5 years no indication of a hostile response so this is applying a risk analysis and you can keep repeating this in all the areas scancell has mentioned in research papers and you will come to the same conclusion ... No negatives Tick Tock

Of Moditope ... the concern by some (boomorbust will remember this discussion) is centred around Humoral immunity or humoural immunity is the aspect of immunity that is mediated by macromolecules found in extracellular fluids such as secreted antibodies, complement proteins, and certain antimicrobial peptides. Humoral immunity is so named because it involves substances found in the humors, or body fluids. It contrasts with cell-mediated immunity. Its aspects involving antibodies are often called antibody-mediated immunity. and in particular ......... anti‐cyclic citrullinated peptide (anti‐CCP) antibodies Moditope is based around Citrullinated peptides so its vital that Moditope does not induce and Antibody response that could induce RA, which is why nobody with this form of auto immune decease can be accepted on the trial (as far as we know) so far in all the research to date it has NOT induced auto- antibodies .......... but that does not stop people thinking and applying risk to it. this is the sort of depth i will go to "derisk" ...... and is the reason by my recent increase in my holding .... because 1/ i still cannot find a negative 2/ Scancell is funded. be very carefully of any one that calls it risky .... because rarely will they be able to explain WHY ...... instead will pontificate the answer quoting other trial failures even thou scancell is the only party to hold a patent in this field as such can never be compared.

through ... lol throw

any research can through up the market potential, in this instance Scancell don't really have to highlight it, after all we are about to run 2 trials with PD1 products, So presentations are trying to target new investors, what i am trying to point out, why would existing investors want to sell (again i post exclude personal reasons and traders) . I also tried to play the risk analysis of why folks hold other stocks, in fairness only Ivy came back on that one, and seemed to be influenced by his friend in his role rather than fundamentals of MTFB because the market potential of scancell is off the charts in comparison again i point to some of the words i have use "Aim capital Gain Shares" PD1 has been approved now in a couple of indications ... with the main market leaders racking in $5 billion per year so to see the market as a whole which moditope encompasses ... $75 billion .. is a mind blowing number considering our market cap Immunobody play to PD1 .. so its so easy to value "synergy" so why is the Mcap �55m and why would any one consider selling ....... For Merck the adjuvant indication could help Keytruda close the gap with Opdivo, which remains the biggest-selling PD-1 inhibitor despite a setback in the big first-line non-small cell lung cancer indication. Both drugs are approved for multiple indications, but Opdivo is still out-selling Keytruda, with the two drugs making sales of $3.6bn and $2.5bn respectively in the first nine months of 2017.

fair enough, and your "risk analysis" is "Your humble opinion"...

Have you switched SCLP to be your major share now from MTFB ? only you seem very keen on Scancell of late

Ivy Posts """ No one should consider that anything is guaranteed and our current valuation reflects this """ show me how you come to calculate that then ... ??? what are you actually basing that on ... another Bio Maybe ?

but you have stated a reason for not signing the deal. that is manipulation ... and the BOD would not think like that. even if you could not prove intent ... morally the BOD would have compromised the market .. then you have one step over the line .... what else would you do ?

You have stated a reason for with holding information, in this case you feel the market would react differently if the signing of the deal with the Uni was delayed

surely that then is manipulation ... which is not in the BOD's interest as the money raised on that day was fixed. like i said why would you sell at 11.8p the lowest price approx .. it made no sense what so ever. which is why the "sellers view" would be of interest

No the legal requirement was that they had to RNS as soon as they had any material information that can affect the SP its by chance that the two moons aligned ...

It would take a stellar performer to knock me over ... because that would in effect knock Lindy over ... that's not going to happen. Because i have constantly shown Scancells science is correct using third party research showing how the synergy works between PD1 and SCIb1 ... Interferon Gamma, and Moditope autophagy and the way Lindy has tuned the CD4 to a th1 response .. I cannot fault or find any evidence that the science has negatives Its interesting that CH considers only the safety issue of Moditope now, Ie once clear of the phase 1 trial of modi1 the risk element collapses leaving us with a land grab patent on autophagy to pursue

Capital requirement Clinical development is capital-intensive. Even though Scancell has successfully obtained a partner to fund the development of SCIB2, it will require more capital to progress its other programmes. Our forecasts include a capital increase of �10m (gross) to fund the trial plans for SCIB1 and Modi-1 and general working capital purposes, which remain modest by industry standards. This would be sufficient to get the company through to a potentially important inflection point in fiscal 2020. we now have this cash ........ so job done !

On funding and the Glycan platform ... was not the best way to market Scancell science these Monoclonal antibodies have been lost in the noise ...

Investment conclusion Scancell is in a strong position, with two novel immunotherapy platforms that are attracting the attention of external partners. The current enterprise value clearly does not reflect the progress that has been made by the company on very limited funds. Newsflow from trial programmes over the next 18 months could be the catalyst for further external attention, and the recent prices paid/proposed by Gilead and Celgene for the immuno-oncology companies Kite Pharma and Juno Therapeutics, respectively, highlight the potential investment returns for novel proprietary platforms/assets. yet many still question why �6 a share is not possible ..... or find it funny ... Its just barmy that anyone would sell at 15p when in reality the Stock has not revalued despite over whelming evidence of scientific and commercial break through

The hardman report contains a lot of info on this subject, the issue is nobody believes it ... which is why i was posting on risk analysis of the science and why would you sell scancell. asking the questions of the seller, but again only stupid comments from Ruckrover came back ... I am afraid the value of the BB is pretty well diminished, to the point that its audience has dwindled to just a few. it only livens up when we get the 20% climbs ...

You can see the issue easily ... no proof that stopping treatment with a 14 month gap would help patients in the long term if it was restarted. from a science point of view its not the intention to create that gap ... so any data yielded is not relevant to the prescribing of SCIB1 in the future.

Trials are about gathering data Following a review with our clinical investigators, it was decided not to continue the SCIB1 long term continuation treatment in the five remaining disease-free patients. These patients have received between six and 17 doses of SCIB1 prior to a dosing holiday of more than 15 months. The Company believes that the effects of any further dosing would therefore be difficult to interpret and to justify to the regulatory authorities.